Pre-clinical toxicology studies and prompt material delivery are essential for IND and CTA approvals, crucial for advancing drug candidates to clinical trials.
To look at combination vaccines, listen to our conversation with Cesar Sanz Rodriguez, vice president, Europe & Switzerland, medical affairs, at Moderna.
Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells. This enables in vivo or ex vivo delivery via a single viral vector. Epic’s lead program, EPI-321, is in IND-enabling studies […]